期刊文献+

不同剂量卡培他滨治疗老年转移性乳腺癌的临床疗效对比 被引量:1

下载PDF
导出
摘要 目的:比较不同剂量卡培他滨治疗老年转移性乳腺癌的临床疗效。方法:选择我院收治的82例老年转移性乳腺癌患者作为研究对象,均给予卡培他滨治疗,根据使用剂量不同分为大剂量卡培他滨治疗组(对照组)和中等剂量的卡培他滨治疗组(观察组),每组41例,观察两组临床疗效及药物副作用。结果:观察组治疗总有效率和总控制率分别为36.6%和80.5%,对照组治疗总有效率和总控制率分别为34.1%和85.4%,差异无统计学意义(P>0.05)。观察组治疗后相关药物毒副反应的发生率明显低于对照组,组间差异有统计学意义(P<0.05)。结论:常规剂量和中等剂量卡培他滨治疗老年转移性乳腺癌的疗效相当,但采用中等剂量治疗后毒副反应发生率较低,耐受性和依从性较好,可在临床推广。
作者 黄静 林川
出处 《北方药学》 2018年第11期59-59,共1页 Journal of North Pharmacy
  • 相关文献

参考文献8

二级参考文献51

  • 1Mariade F,Gilberto Amorim,Roberto Arcuri,et al.A phaseⅡstudy of second-Line neoadjuvant chemotherapy with capecitabineand radiation therapy for anthracycline-resistant locally advancedbreast cancer[J].Am J Clin Oncol,2007,30(1):78-81.
  • 2Fumoleau P,Largillier R,Clippe C,et al.Multicentre,phaseⅡstudy evaluating capecitabine monotherapy in patients withanthracycline-and taxane-pretreated metastatic breast cancer[J].Eur J Cancer,2004,40(4):536-542.
  • 3Gridelli C,Perrone F,Cigolar S,et al.The MILES(multicenteritalian lung cancer in the elderly study)phaseⅢtrial:gemcitabine+vinorelbine vs vinorelbine vs gemcitabine in elder advancednon-small cell lung patient[C].Proc Am Soc Clin Oncol,2001,20:308a.
  • 4Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individu- al patient data from capecitabine monotherapy clinical trials in lo- cally advanced ormetastatic breast cancer [ J ]. Breast Cancer Res Treat,2012,136 ( 3 ) :777 - 788.
  • 5Zielinski C, Gralow J, Martin M. Optimising the dose of capecit- abine in metastatic breast cancer: confused, clarified or confirmed? [J]. Ann Oncol,2010,21 ( 11 ) :2145 -2152.
  • 6Molina-Garrido M J, Mora-Rufete A, Guillen-Ponce C. Oral chemo- therapy in elderly women with metastatic breast cancer [ J ]. Anti- cancer Agents Med Chem ,2014,14 (5) :665 - 672.
  • 7Bajetta E, Procopio G, Cello L, et al. ferent doses of capecitabine in the cancer in older women [ J ]. J Clin -2161. Safety and efficacy of two dif- treatment of advanced breast Oncol, 2005,23 ( 10 ) : 2155.
  • 8Zhou Y, Peng L2, Li Y1, et al. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syn- drome : A meta-analysis [ J ]. Biomed Rep,2013,1 (6) : 873 - 878.
  • 9Khatcheressian J L,Hurley P,Bantug E,et al.Breast cancer follow-up and management after primary treatment:American Society of Clinical Oncology clinical practice guideline update[J].J Clin Oncol,2013,31(7):961.
  • 10Nishino M,Jackman D M,Hatabu H,et al.New Response Evaluation Criteria in Solid Tumors(RECIST)guidelines for advanced non-small cell lung cancer:comparison with original RECIST and impact on assessment of tumor response to targeted therapy[J].AJR Am J Roentgenol,2010,195(3):221.

共引文献67

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部